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INTRODUCTION 
Systemic lupus erythematosus (SLE) is an autoimmune disorder with multisystem involvement. 
It predominantly involves adolescent girls. 20% of all SLE begin in childhood after 5 years of 
life. It is more predominant in females with a female to male ratio of 8:1. The ratio lowers down 
to 2:1 in the pediatric age group(1,2).  
The Etiology of systemic lupus erythematosus is unknown. Environmental factors (UV light, 
drugs, toxins and infection) may play a role in the genetically predisposed population. The 
pathogenesis is complex. The autoantibodies, polyclonal B cell activation  and the T cell 
dysfunction contributes significantly to the disease activity (3).  Lupus nephritis is very common 
among the pediatric population. It is reported that about 40-75% of patients diagnosed to have 
SLE, develop lupus nephritis within 5 years of diagnosis and almost all patients have a degree of 
glomerular abnormality. The risk of development of end stage renal disease is 18-50%(44,5). 
High dose corticosteroids have improved the course of lupus nephritis. However in the last 20 
years additional treatment  including the use of cytotoxic therapy has increased the 10 year 
survival to 80% (6). 
 
Mycophenolate Mofetil (MMF) is an immunosuppressant that is routinely given for treatment of 
acute graft rejection and for prophylaxis following solid organ transplant.  MMF is the 
norphlinoethyl ester of mycophenolic acid (MPA). MPA inhibits the denovo purine synthesis. 
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Lymphocytes are selectively inhibited because lymphocytes rely on de novo synthesis of purines 
(7). MMF also depletes the lymphocytes and monocytes of guanosine triphosphate by selectively 
inhibiting inosine monophosphate dehydrogenase(8).  Successful use of MMF in lupus nephritis 
has been described in various studies(7,9). MMF is also known to produce lower rates of 
infection and cytopenia compared to patient who are treated with cyclophosphamide(10).  
However the optimum dose of MMF in lupus nephritis has not yet been defined. The pediatric 
post organ dose of 30mg/kg twice daily or 600mg/m2 twice daily is being followed for the 
treatment of lupus nephritis(11).  A fixed dose of 0.5 g to 1.5 g bid adjusted to the tolerance of 
the individual is also being followed in the treatment of lupus nephritis(12). A target 
concentration of MPA that is aimed at is 30-60 mg h/L. Also there is an inter-individual 
variability of MPA concentrations for a given dose of MMF and the MPA concentrations also 
depend on whether the drug is given along with other drugs like cyclosporine or tacrolimus(13). 
We try to demonstrate the inter-individual variability of MPA concentrations for a given dose of 
drugs and also co-relate the association between the disease activity as measured by the SLE 
disease activity index (SLEDAI) and the concentration of the drug. 
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LITERATURE REVIEW: 
HISTORY: 
The history of lupus dates back to the 13
th
 century when the physician Rogerius described the 
lesions as wolf bite. Lupus in Latin means wolf. Incidentally that is when the term lupus was 
coined(14). It was then considered to be a cutaneous disease. Only in the latter half of the 19
th
 
century was it recognized as a multisystem disease after the works of Kaposi. 
 
DISEASE BURDEN: 
 Systemic lupus erythematosus is an autoimmune disorder with multisystem involvement and is 
potentially fatal.  The prevalence of lupus ranges from 40 per 100,000 persons among the 
Europeans. Among blacks the prevalence is as much as 200 per 10,000 persons(15).  In a study 
from Asia 15 to 20% of all lupus is diagnosed in the pediatric age group (16 years and less).The 
prevalence of lupus in the pediatric age group of the Asian population was found to be 6.3 to 
10.3 per 100,000 (16). 
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ETIOLOGY: 
The etiology of lupus is unclear. Around 90 % of lupus is females. Hence the contributory role of 
female sex hormones and the protective role of male sex hormones are possible. Buyon et al 
concluded that, the post menopausal women with SLE who received hormonal replacement with 
conjugated estrogen and progesterone were more prone for disease flare than the patients 
receiving placebo(17).  But clinical trials which involves administration of 
dihydroepiandrosterone for the treatment of lupus has not been promising (18). 
 
Genetic Factors 
There is a possible genetic role in the etiology of SLE. It tends to occur in families. However 
there is no clear cut Mendelian inheritance. There is more occurrence of the disease in families. 
There is 2% increased risk of disease in a sibling with SLE. However in even monozygotic twins  
there is only 25% increased risk of disease and in dizygotic twins the risk is even lower(19). 
These rates mean that there is not enough evidence for a genetic role. Many genes have been 
identified after genome-wide genetic association studies in families with multiple lupus patients 
which possibly contribute to the disease(20). Certain genes for the major histocompatibility 
proteins namely HLA A1, B8 and DR3 are associated with lupus (21). 
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Early complement component( C1q, C2 or C4) deficiency is strongly associated with lupus (22). 
Family studies have identified many genes in patients with lupus. Their function is to code for 
components of the Immune system. A Scandinavian study showed that a single nucleotide 
polymorphism  in two interferon-related genes coding for tyrosine kinase 2 and interferon 
regulatory factor 5(23). In mice studies Wakeland identified three genetic loci that are associated 
with lupus namely sle1, sle2 and sle3. Sle1 gene mediates the loss of immunological tolerance to 
nucleolar autoantigens. Sle 2 and Sle3 mediates B cell hyperactivity and T cell dysregulation 
respectively(20). 
 
Environmental factors 
Drugs like hydralazine, procainamide and quinidine are known to cause drug-induced lupus. The 
drug induced lupus presents with rash and joint pain and generally do not cause nephritis and 
CNS manifestation (24).  Ultraviolet radiations has been identified as the most important 
environmental factor in causing lupus(25,26). Preceding viral infections are noted before the 
presentation of prior to a flare. Particular causative virus has not been described yet. However 
Ebstein-Barr(EBV) virus is possibly associated as disease presentation and the infection 
occurring simultaneously has been reported(27). A case control study showed that EBV DNA 
was present in 100% of cases with lupus. 
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Auto-antibodies in lupus   
Autoantibodies play a major role in the pathogenesis of lupus.  Kidneys of patients with lupus 
nephritis were demonstrated to have antibodies which bound to native double stranded DNA(Ds-
DNA) (28). Anti-Ds-DNA is present in as many as 70% of patients with lupus. It is also present 
in about 0.5% of healthy individuals and in individuals with other connective tissue like 
rheumatoid arthritis(29). It is strongly associated with the disease activity(30).Patients with anti-
ds-DNA positivity and clinically asymptomatic have a 80% chance of having active disease in 5 
years(31). In other post mortem renal biopsy studies by  Mannik et al there was evidence of auto 
antibodies against non DNA proteins like Ro (ribonucleoprotein complex), La (RNA binding 
protein), Sm (nuclear particles) and C1q( a subunit of C1) (32).  Anti-ribosomal P antibodies are 
more common in childhood nephritis  and is positive in severe nephritis(33). The presence of 
anti-RO or anti-LA or both during pregnancy is associated with 1 to 2 % risk of fetal heart 
block(34) . 
Anti-N-methyl d-aspartate (NMDA) may be important in CNS lupus. Kawal showed that 
antibodies against NMDA and DNA produced cognitive impairment in patients with lupus and 
hippocampal damage in mice models (35). Anti Ro and anti-nucleosome antibodies are seen in 
cutaneous lupus. Anti-nucleosome antibody is seen in skin biopsy specimens in patients with no 
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active skin lesion but active nephritis(36). Hemolytic anemia and thrombocytopenia in lupus 
occurs secondary to antibody mediated destruction of platelets and red blood cells.(37) 
 
There are two theories of damage caused by autoantibodies. Berden et al suggest that auto 
antibodies against the double stranded DNA (anti ds-DNA) bind to the nucleosome which are 
released into the cytoplasm and this compound deposits in the  glomerular basement membrane 
thereby causing glomerulonephritis(38). In animal models this nucleosome- autoantibody 
complex is studies to initiate complement activation(39). The second theory states that both anti-
nucleosome antibody and anti-ds-DNA both cross react with proteins in the kidney and thereby 
causing damage(40). 
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Clinical manifestations: 
Systemic lupus erythematosus presents in children acutely and usually with multisystem 
involvement. Fever, musculoskeletal symptoms, fatigue and anorexia are the common 
presentation. 
 
 Arthritis is usually found in 50-75% of the individuals. The arthritis in lupus is characteristically 
non deforming and non erosive (41).  Arthritis may be symmetrical, painful polyarthritis which 
affects both small and large joints. The ultrasound study in the joints affected showed 
tenosynovitis with thinning of the tendon(42). 20-30% of children have myalgia. Although 
myositis is rare when present makes it difficult to differentiate it from dermatomyositis. 
 
Mucocutaneous involvement is seen in 60-80% of patients with pediatric SLE at the time of 
presentation. The rash associated with SLE is the malar rash a maculopapular rash which 
involves the malar area and the bridge of the nose. It is usually photosensitive and resolves 
without any residual scarring. A discoid lesion is uncommonly seen in lupus. It is photosensitive 
and occurs in the forehead and scalp (43). The malar rash that is known to be commonly 
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associated with the disease is not very frequently seen in Indian children. The presence is also 
not pathognomonic of the disease(44).The oral mucosal lesions  are hyperemia and ulcerations 
usually seen in the hard palate and are characteristically painless. Mild alopecia may be the 
presenting feature. It can also be severe (45). 
 
Hematological manifestations are seen in about 100% of patients. The ethnic background plays a 
large role in the incidence of hematological manifestation. Anemia is seen in 75% of the Indian 
children. Anemia of chronic disease is most commonly seen in SLE. The anemia is initially 
normocytic normochromic and later microcytic hypochromic. 30-40% has Coomb positivity. 
However only10-15% of them have overt hemolysis (46). 15 to 45% of patients have 
thrombocytopenia. It can be the presenting feature in 15% of the patients. Children who present 
with autoimmune thrombocytopenia should be evaluated routinely for lupus  in view the high 
incidence(47).  Leucopenia ( both lymphopenia and granulocytopenia) is found in 20-40% of 
individuals(48). Coagulation abnormalities are seen. 20% of patients with pediatric SLE have 
lupus anticoagulant positivity. They usually have thromboembolic events. They have 20-30 
times increased chance of have a thromboembolic event (49).  The commonest cause for 
secondary antiphospholipid syndrome is systemic lupus erythematosus in children. Lupus may 
also manifest many years after presentation of primary antiphospholipid syndrome(50). It present 
as thromboembolism and venous events are more common than arterial events(49). 
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Among the cardiovascular manifestations Pericarditis with pericardial effusion is the most 
common. Mild pericardial effusion which is picked up by echocardiography is seen in1/3
rd
 of the 
patients. However overt pericardial effusion is seen in 25-40% of the individuals(41,44).  
 
Pleuropumonary involvement is seen in 25 – 75% of patients (51).Pleuritis is the most common 
manifestation. Acute lupus pneumonitis may present similar to infective pneumonia or 
pulmonary hypertension(52).5-10% of lung manifestations re pulmonary hemorrhages (53). 
Pulmonary hypertension secondary to pulmonary vascular disease is a rare but potentially fatal 
complication(54) 
 
Involvement of the central nervous system is reported in a wide range of patients. It may occur in 
as low as 20% to about 90% of patients(55). The reason for this wide variation in the incidence 
of central nervous system complications is because of the discrepancy in the definition of certain 
central nervous system symptoms. The commonest neuropsychiatric manifestation is Lupus 
headache. Lupus headache is defined as an unremitting headache which requires narcotic 
treatment (56).  30-50% of neuropsychiatric manifestations are contributed by psychosis, They 
more commonly have visual hallucinations and less commonly auditory and tactile 
hallucinations in that order. They characteristically have preserved insight(57).  12 to 30% of 
patients with neuropsychiatric manifestations have cerebrovascular disease(58). 10-20% of 
children with CNS lupus have cerebral venous thrombosis and are almost universally associated 
with lupus anti coagulant(49). 
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Abdominal pain and diarrhea are the most common gastro intestinal manifestations(59).  When 
associated with vasculitis if the gastrointestinal system the patients are at risk of developing an 
intestinal perforation(60). Pancreatitis is a rare complication presenting in about <5% of the 
cases. Patients usually present with vomiting and diffuse abdominal pain(61).  
 
Ocular finding that is most associated with lupus is cytoid bodies. This is secondary to retinal 
vasculitis(62). 
 
Infectious complications are extremely common and are a major cause of death. They create 
diagnostic and therapeutic challenges. In the presence of fever along with respiratory symptoms 
or central nervous system symptoms like seizures, altered behavior infection needs to be ruled 
out. If investigations show high counts with neutrophilic predominance which is unlike SLE 
sepsis needs to be ruled out. However counts may not be necessarily high in the setting of 
infection as patients with SLE may have apparently normal counts during infection as their 
baseline counts may be low. An elevated CRP also suggests infection. Opportunistic infections 
like tuberculosis and fungal also needs to be considered.  
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Lupus nephritis is very common among individuals with SLE. Almost all patients are reported to 
have some degree of glomerular abnormality. About  40-75% of patients with SLE develop 
clinical nephritis within 5 years of diagnosis(63). The risk of progression to end stage renal 
disease is 18-50% (4,5).  The presentation of lupus nephritis can vary extensively from 
individual to individual. It can range anything between mild nephrologic abnormality to rapidly 
progressing and nephrotic syndrome.  Hematuria and proteinuria are the most common. 
Hematuria is present in 67-100% of individuals with lupus nephritis whereas nephritic syndrome 
is present in about 50% at diagnosis. Hypertension and renal insufficiency is seen in 50% of 
affected individuals(5). Age related disease manifestations were studied. Children were found to 
have higher incidence of hypertension, proteinuria, hematuria,  cellular casts  and Creatinine(64). 
 
Patients with hematuria and/or proteinuria may have any class of glomerulonephritis.  The 
prognosis depends on the stage of renal involvement and it is of utmost importance in deciding 
the treatment (65). Children with silent disease may have major histopathological abnormalities. 
Hence the clinical picture always does not correlate with the renal histopathology(6).  WHO 
developed a classification for lupus nephritis in 1973 which helps in prognosis and deciding on 
further therapy.  The classification uses light microscopy,  immunofluorescence and electron 
microscopy(6). 
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WHO has classified lupus nephritis as follows (66) 
Class I : Normal glomeruli  a) Normal by light microscopy b) immunological deposits by 
electron microscopy 
 
Class II: Mesangiopathy. a) Pure mesangial widening with mild hypercellularity b) moderate 
hypercellularity 
 
Class III: Focal and segmental glomerulonephritis a) active and necrotic lesions b) active and 
sclerosing lesion c) sclerosing lesions 
 
Class IV: Diffuse proliferating glomerulonephritis (severe mesangial, mesagiocapillary or 
endocapillary and /or extensive subendothelial deposits) without segmental lesions b) with 
“active” necrotizing lesions c) with active and sclerosing lesions d) with sclerosing lesions 
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Class V: Diffuse membranous glomerulonephritis a) pure membranous glomerulonephritis b) 
associated with lesions of category IIa or IIb. C) Associated with lesions of category III (a-c) d) 
associated with lesions of category IV (a-d) 
Class VI: Chronic sclerosing glomerulopathy 
Treatment of lupus nephritis: 
Clinical trials in the pursuit of treatment for SLE started as early as 1894 when Payne reported 
the beneficial effects of quinine in SLE. Brief period later salicylates were proved beneficial. But 
the break-through in the treatment of lupus was not attained until the 1950s when Hench reported 
the efficacy of cortisone in the treatment of rheumatological conditions like SLE (67) and ever 
since steroids have been the primary therapy in the treatment of SLE. 
 
However the ideal treatment for SLE nephritis is unclear despite years of research primarily 
because of the basic pathophysiology. It is not clear whether the excess B cell activity or 
defective T cell suppressor activity or excess helper T cell activity is being dealt with(68). 
 
With the advent of the recent treatment options the outcome of pediatric SLE has improved 
dramatically over the past years. The 10 year survival rate in the 60’s was as low as 30%  and in 
the early 90’s it has improved to excess of 90%(69).  Non renal causes like infections has 
replaced renal failure the common cause of death in Lupus(70). The treatment needs to be 
balanced between an aggressive initial therapy to control disease activity and a maintenance 
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therapy aimed at minimal aide effects. Delayed onset of treatment is associated with poorer 
outcome(71). 
 
 
Therapy of class I, II nephritis: 
Patients with class I nephritis are very rare and no specific treatment has been described. There is 
no specific treatment described for the treatment of class II nephritis either. Corticosteroid, as a 
long term treatment of lupus nephritis is not indicated. It is rather aimed at associated extra-renal 
manifestations of lupus(64).  However there is need for long term follow up for the progression 
of disease 
Therapy of class III, IV nephritis: 
The course of the disease in class III lupus nephritis is the same as that of class IV when more  
than 40% of glomeruli are involved and hence the same aggressive therapy is needed(6). 
However if less than 20% of glomeruli are involved , the prognosis is quite good with <5% of 
patients progressing to end stage renal disease at the end of 5 years(72). 
Patients with Class IV lupus nephritis (Diffuse proliferative lupus nephritis)  is prone for 
hypertension , nephrotic syndrome and end stage renal failure. Prompt treatment is warranted in 
class IV lupus nephritis. Corticosteroids have dramatically changed the course of the disease. 
Recent studies have shown that low dose corticosteroids are as equal in efficacy as high dose 
corticosteroids. In fact high dose corticosteroids are associated with serious side effects (73).  
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Sterinberg et al assessed 111 children and  concluded that the patients in the study arm which 
involved treatment with a cytotoxic drug plus low dose prednisolone had significantly better 
preservation of renal function compared to those treated only with high dose steroids(74). 
 
Unlike adults treatment with corticosteroids and immunosuppressants are required in the 
treatment of Child hood SLE(75). Treatments that are currently used are antimalarials, 
corticosteroids, cyclophosphamide, azathioprine and mycophenolate mofetil. 
Corticosteroids: 
For over two decades the teaching was to treat diffuse proliferative glomerulonephritis with high 
dose corticosteroids. Recent studies show that high dose steroids are no better than low dose 
steroids and are associated with unwarranted side effects.  In his randomized control trial 
Steinberg demonstrated that patients randomized to the groups treated with cytotoxic therapy in 
addition to steroids had better preservation of renal function that did the group treated with 
prednisolone alone(74). Pulse methylprednisolone administered intravenously as pulse doses 
leads to dramatic improvement in patients with acute deterioration of renal function(76). 
However the long term effect of this regimen in preserving renal function matched only 
prednisolone. Also intravenous methylprednisolone is associated with side effects like cardiac 
arrhythmias and cardiac arrest. Other side effects like flushing sensation, acute hypertension and 
acute psychosis are also associated(77). 
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Cyclophosphamide: 
There is much evidence that combination of cyclophosphamide with steroids has better results in 
preserving the renal function than steroids alone
55
.  Cyclophosphamide is metabolized in the 
liver to its active metabolite. The active metabolite alkylates the macromolecules(78). Initially 
oral regimens in the dose of 1-3mg/kg/day for 8-12 weeks were described. Currently monthly 
boluses at a starting dose of 750mg/m
2 
is suggested to be less toxic than oral daily doses at 
2mg/kg(79). The dose of cyclophosphamide may be increased to 100mg/m
2
 if the WBC count 
remains more than 3000/mm
3
. The duration of therapy after the initial control of disease is not 
well described. In his study Lehman used cyclophosphamide for 3 years and reported 
improvement in hemoglobin C3, C4 and Creatinine clearance(80) 
Cyclophosphamide therapy is associated with the risk of toxicity which includes alopecia, bone 
marrow suppression , gonadal failure, hemorrhagic cystitis and development of malignancy(81).  
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Azathioprine: 
Azathioprine is an antimetabolite that interferes with protein synthesis(78). It has been proved to 
be safe when given in the log-term. It is given in the doses of 2-2.5mg/kg per 24 hours. It may be 
used with prednisolone in the initial treatment of lupus nephritis(82) and later substituted for iv 
cyclophosphamide after 6 months if the disease is well controlled. It can also be given after 
completing 8-12 weeks of oral cyclophosphamide(64). When Azathioprine is given in 
combination with steroids the steroid dose has to be changed in the event of withdrawing 
Azathioprine as the disease may relapse. This is because of the steroid sparing effect of 
azathioprine(83) .  Azathioprine is relatively safe, however long term administration causes bone 
marrow suppression which is reversible on discontinuation(84) 
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Cyclosporine A 
It is a relatively new drug which is used in the event of steroid resistance or in severe steroid 
toxicity. It acts by interfering with the production of lymphokines produced by the 
lymphocytes(85). Cytotoxic T call recruitment is stopped by inhibiting production of  
interleukin-2 and thereby decreasing  inflammation(64). Cyclosporin used along with steroids is 
known to decrease proteinuria and improve renal function with better growth rate as compared to 
patients treated with prednisolone and cyclophosphamide combination and its use alone(85). 
Side effects are minimal. Hypertension, transient elevation of serum Creatinine, hypertrichosis 
and gingival hyperplasia.(64)  
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Mycophenolate Mofetil: 
Mycophenolate mofetil is a relatively new drug which has been used routinely in the prophylaxis 
against graft rejection and in its treatment in the post renal transplant patients. Mycophenolate 
mofetil (MMF) is immunosuppressive drug which acts by irreversibly inhibiting the enzyme 
inosine monophosphate dehydrogenase (IMPDH) and hence selectively inhibiting proliferation 
of T- cells and B cells as they require de-novo synthesis of purines(86). Mycophenolic acid 
(MPA) is the active form of the inactive prodrug mycophenolate mofetil (MMF). MMF is 
converted to MPA by liver, plasma and intestinal esterases (87).  There are many recent studies 
which show that mycophenolate mofetil is as efficacious or atleast comparable with 
cyclophosphamide in the induction treatment of childhood systemic lupus erythematosus(88,89). 
MMF is also known to produce lower rates of infection and cytopenia compared to patient who 
are treated with cyclophosphamide(10). 
 
 The dose recommended in clinical practice is based on clinical trials for renal transplantation. It 
is a fixed dose of 2 to 3 grams per day in divided doses. Other evidences based on 
pharmacokinetic studies in children with autoimmune diseases, a dose of 900mg/m2 is suggested 
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in children. The dosage is lower than in patients who have undergone solid organ transplantation 
(1200 to 2400 mg/m2) who simultaneously receive calcineurin inhibitors. In renal transplantation 
therapeutic drug monitoring has been developed for individualization of doses. MPA area under 
the plasma concentration time curve from 0-12(MPA AUC0-12 hrs) has been successfully 
correlated in the outcome of patients who have undergone solid organ transplantation(90).  
 
The MPA pharmacokinetics in patients with systemic lupus erythematosus is different from the 
patients who have undergone solid organ transplants who are on Cyclosporin A (91,92) .  
Patients with SLE often have a third peak in the AUC due to the absence of calcineurin 
inhibitors. Plasma concentration of MPA are reduced by cyclosporine as it inhibits the  
enterohepatic circulation of MPA(93,94). Target concentration of AUC over 12h of 30-60 mg h/l  
when measured with high performance liquid chromatography or 35 to 70 mg h/l when measured 
by enzyme multiplied immunotechnique is advised for patient undergoing renal transplant (95). 
(12).  
 
A target concentration of MPA that is aimed at for the therapy of lupus nephritis is also 30-60 
mg h/L. Also there is an inter-individual variability of MPA concentrations for a given dose of 
MMF and the MPA concentrations also depend on whether the drug is given along with other 
drugs like cyclosporine or tacrolimus(13).    
 
28 
 
 
The target concentrations of MPA in children treated with MMF for SLE is very important as 
this reflects the clinical outcome and the association with side effects. There are very few studies 
which have reported the inter-individual variability of MPA concentration and even fewer in 
children. Filler et al studied 5 children with autoimmune diseases and compared the 
pharmacokinetics of mycophenolate sodium (EC-MPS) with pharmacokinetics of mycophenolate 
mofetil (MMF). Factors affecting inter-individual variability are studied in transplanted 
individuals. Patients with renal insufficiency (creatinine clearance of <25ml/min) and low 
albumin (32g/l) have low MPA exposure because MPA clearance depends on its non protein 
bound fraction(96). Both hypoalbuminemia and renal insufficiency results in a high free fraction 
of MPA and hence increased clearance of MPA(92,97).To our knowledge the target 
concentration of MPA in children with Lupus nephritis has not been discussed till date. 
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AIMS 
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AIMS: 
1) To determine whether MPA AUC 0-12 correlates with disease activity in children with 
lupus nephritis on mycophenolate mofetil 
 
2) To demonstrate the inter individual variability of the MPA concentration in children 
taking MMF 
 
3) To determine the independent variables that correlate with MPA AUC 0-12. 
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MATERIALS AND METHODS 
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Materials and Methods: 
 
a. Study setting:  
The recruitment for this study took place at the pediatric rheumatology clinic of Christian 
Medical College, Vellore.  The OPD functions on 3 week days (Wednesdays, Fridays and 
Saturdays) a week. The OPD serves on an average about 40 patients which includes 5 -10 
patients with systemic lupus erythematosus. 
 
Children whose parents are willing to take part in the study are recruited after an 
informed written consent. Children were recruited over a period of 6 months from March 
2012 to November 2012. 
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b. Participants: 
       Inclusion criteria: 
*Children diagnosed to have systemic lupus erythematosus as per American College of 
Rheumatology criteria with proliferative lupus nephritis (Class III and IV) and treated with 
similar doses of prednisolone 
*Children aged between 8 and 18 years 
*Children who have received stable doses of MMF for atleast 1 month. 
 
Exclusion Criteria: 
*Children with SLE aged >18 years 
*Children with SLE who had Class II or Class V Lupus nephritis 
*Children taking MMF not on empty stomach or taking not on regular intervals 
*Children who have developed significant side effects to MMF like diarrhoea and marrow 
suppression 
*Children with lupus nephritis with concomitant drugs like cyclophosphamide, cyclosporine, 
tacrolimus or azathioprine 
 
 
 
34 
 
 
c. Variables: 
Exposure: All children with proliferative lupus nephritis on MMF for at least one month 
(standard dose 50 mg/kg/day) 
Outcome: MPA AUC correlates with disease activity as measured by SLEDAI 
Predictors: Dose of MMF, Disease activity, C3, C4, Albumin, Creatinine 
d. Data Sources/measurement:  
Complete blood count: Sample is sent in an EDTA tube and sent to the clinical 
pathology lab. Blood is processed in the Beckwith coulter machine and the validated 
results are considered. 
Serum creatinine: 2ml blood is collected in a clotted tube and sent to the biochemistry 
lab. Creatinine is calculated by the picric acid method. The values are measured in  
Total complements/C3, C4: 2ml of blood is collected in a clotted tube and sent to 
microbiology lab. Serum complements (C3 and C4) are measured by the nephelometry 
method. 
Ds-DNA: Blood is processed in the autoimmune lab by the ELISA method. 
Urine protein creatinine ratio: Spot urine sample is processed in the biochemistry lab 
by the Pyrogall indicator method. 
 
 
 
35 
 
 
e. Sample size: A total of 25 children who fulfilled the inclusion criteria  were recruited 
 
f. Statistical methods:  
 
 The quantitative variables were presented using the mean and standard deviation. 
  All categorical variables were presented using the frequencies and percentages  
 . The mean MPA values were compared across male and female using independent t test.   
 The comparison of MPA across BSA values was compared using Mann Whitney U test. 
Spearman Rank correlation was used to find the relationship between MPA and all 
continuous variables.  
 .All the variables that were significant from the bivariable analysis were included for 
multivariable regression analysis 
 Data analysis were done with SPSS Version 17  
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Methodology: 
Children with systemic lupus erythematosus with lupus nephritis who have been on MMF for 
the induction or maintenance therapy were inducted for the study.  Most importantly children 
should have been on the drug for at least 1 month and the intake of drugs should be organized 
and appropriately spaced through the day.  An informed, written consent was obtained for each 
patient after detailed one to one discussion with the parents/patient. After the consent, the child 
was examined.  
 
After getting the informed written consent from the patient/ guardians the patient is asked to 
give blood for complete blood count, serum Creatinine, serum albumin, complements and anti-
ds DNA.. The patient is also asked to give urine for routine analysis and for spot protein 
Creatinine ratio. After the results are available the disease activity is assessed with the SLE 
disease activity index scoring (SLEDAI) system. The patient is instructed to take the tablet at 
the usual dose and given instructions to come fasting and not to take the next day’s morning 
dose. The patient is instructed to come to the clinical pharmacology unit the next day on an 
empty stomach. In the clinical pharmacology lab an IV cannula is inserted in situ and blood for 
trough MPA level is taken after which the line is flushed with heparin saline. The child is then 
instructed to take the drug. After the baseline (trough) sample, samples are taken at 0.5, 1, 1.5, 
2, 2.5, 3, 4, 8 and 12 hours after MMF administration. The specimen will be centrifuged and 
plasma separated into a clean eppendorf tube. All specimens will be stored at – 20
o
C until 
analysis.  
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Plasma MPA concentrations will be determined by high performance liquid chromatography 
(HPLC). Plasma concentration data will be used to estimate the concentration time curve 
(AUC0-12). The patients’ AUC 0-12 concentration is determined and compared with the clinical 
status and the serological status. It is postulated that a high drug concentration level will 
correspond with a lower disease status viz normal complements and a negative ds-DNA as well 
as clinical remission(86). It will also be tried to ascertain the optimal drug concentration to 
induce or maintain remission. To my knowledge there has not been any such study on the 
Indian population and very few studies overseas have been done on children with SLE. 
This study is approved by Institutional Review Board (IRB) of Christian Medical College, 
Vellore (No 7702.) 
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RESULTS 
Patient characteristics: 
Twenty-five outpatients who fulfilled the inclusion criteria were recruited for the study. Out of 
25 children, 20 were girls and 5 were boys (Fig1). Out of the twenty five, 16 children received 
2gms/day, 7 received 1.5gms/day and 2 received 1gm/day. Indications for administering MMF 
were lupus nephritis class III (n=8), lupus nephritis class IV (n=17) (Fig2). On the day of study, 
13 patients were receiving concomitant prednisolone and 22 children were receiving 
Hydroxychloroquine. SLEDAI scores done on all 25 children showed that 5 patients (21%) had 
active disease (SLEDAI score ≥6) and 20 patients (79%) had inactive disease (SLEDAI score<6) 
on the day of sampling (Fig3).  
 
 
 
 
 
 
 
 
 
40 
 
 
Table 1. Baseline characteristics of patients with active and inactive SLE 
 
 
 
MPA AUC0-12:= Mycophenolic acid Area under the curve 0-12 hours, Ds-DNA:=double stranded 
deoxyribonucleic acid 
 
The active and inactive disease groups were similar in age (mean age was 15.0 ±3.3 in the active 
disease group and was 14.75±1.7 in the inactive disease group).The two groups were also similar 
in weight, height and serum albumin levels.  Hemoglobin, C3 and C4 levels were statistically 
significant between the two groups (p < 0.05) 
 
 
Parameters (Normal range) 
 
Active SLE 
(SLEDAI ≥6) 
n=5 
Inactive SLE 
(SLEDAI <6) 
n=20 
p value 
Age 15.0±3.3 14.75 ±1.7 0.272 
Height (Cms) 151.8±12.3 152.9±8.8 0.974 
Weight ( Kgs) 48.6±12.39 48.35±12.21 0.767 
Creatinine (0.7 to 1.1 mg/dl) 0.8±.18 0.78±.11 0.92 
Serum Albumin (3.5 to 5 gm/dl) 4.08±.5 4.4±.36 0.272 
Anti-ds-DNA (<100 IU/ml) 240±62 156.9±227 0.060 
Total count   /Cu.mm 8740±2967 8900±3078 1.000 
Hemoglobin ( gm%) 10.2±1.9 12.3±0.72 0.007 
C3 level (90-180 mg/dl) 66.12±13.29 99.69±15.59 0.001 
C4 level (10-40 mg/dl) 8.1±3.5 18.8±6.9 0.001 
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Figure1: Showing the sex distribution among the participants 
 
 
 
80% of our patients were girls (n=22) and 20% were boys (n=3) 
 
 
 
Female 
n=20, 
(80%)
Males n=5  
(20%)
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Figure 2. Lupus nephritis class among the patients 
 
 
Our participants predominantly had class IV nephritis. 
 
 
 
 
Class III
8
(32%)
Class IV
17
(68%)
43 
 
 
Fig3: Distribution of disease activity among the participants 
 
 
 
 
80% of the participants (n=20) had inactive disease(SLEDAI score<6) on the day of 
examination.20% (n=5) had active disease (SLEDAI score≥6). 
 
SLEDAI≥6, 
n=5,   
(20%)
SLEDAI<6, 
n=20, 
(80%)
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Figure 4. Correlation of C3 levels with SLEDAI 
 
 
 
 
SLEDAI:=Systemic Lupus Erythematosus  Disease Activity Index 
 
 
Low C3 was significantly correlated with high disease activity (P=0.001) 
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Figure 5. Correlation of C4 with SLE disease activity 
 
 
 
 
 
Low C4 was significantly correlated with high disease activity (P=0.001) 
 
 
 
 
 
 
 
 
0
5
10
15
20
25
0 5 10 15 20 25 30 35 40
C
4
SLEDAI                                          p=0.001
SLEDAI
46 
 
 
 
Figure 6: Correlation of hemoglobin and SLEDAI 
 
 
 
 
 
 
 
 
Hemoglobin correlated significantly with disease activity (SLEDAI scores) 
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Fig7: Correlation of MPA AUC0-12 with SLE disease activity  
 
 
MPA AUC0-12:= Mycophenolic acid Area under the curve 0-12 hours 
 
 
High SLEDAI scores correlated with low MPA AUC  0-12  on the day of  examination(P=0.003) 
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Inter-Individual variability: 
 
Fig8.Between-patient variability of MPA AUC0-12 /gm of MMF 
 
MPA:-Mycophenolic acid 
 
MPA AUC0-12 showed wide variability (Fig8) with lowest level of 22.1 and a highest level of 
104µg.hr/ml. The mean ±SD MPA AUC0-12 of the active disease group (38.46±14.3µg.hour/ml) 
was significantly lower than that of the inactive group (69±19.24µg.hour/ml) with a p value of 
0.003.  
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Table 2 Parameters influencing MPA AUC0-12 levels 
BSA: =Body Surface Area 
 
A univariate and multivariate regression was done to predict the factors influencing MPA AUC0-
12 levels. Factors included were sex, body surface area, dose of MMF, albumin and C3 levels. 
Only MMF dose was found to be significantly influencing the MPA AUC0-12.  
 
 
 
       
    
UNIVARIATE 
                  
MULTIVARIATE 
 
 
 
 SD P value   95%CI P value 
 
Sex Male   64.1±22.6   0.593  -28.9 - 18.2  .65 
Female   58.1±20.6       
BSA <1.5   66±23.26  0.31  -33.8-52.3  .67 
>1.5   56.2±18.5       
 
Creatinine 
clearance 
     <90                 56.0±0  0.8 
 
 
 
-18.3 – 65.73  .27 
             
     >90  63.1±22.4      
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Figure 9 Correlation of MPA AUC-0-12 with dose of MMF 
 
 
 
 
 
 
Higher the dose of MMF correlated to better MPA levels(Fig9). 
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Fig10. Correlation of albumin with MPA AUC 0-12 
 
 
 
 
 
Serum albumin was not significantly associated with MPA AUC0-12  
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Figure 11. Showing correlation of C3 with MPA AUC 0-12 
 
 
 
C3 did not correlate significantly with MPA AUC0-12 (fig 11) . 
 
 
 
 
 
 
 
 
0
20
40
60
80
100
120
0 20 40 60 80 100 120 140
C
3
MPA AUC0-12                                      P=0.43
MPA 
53 
 
 
Figure 12. Showing correlation of age with MPA AUC 0-12 
 
 
 
 
 
 
There was no significant correlation between age and MPA AUC 0-12  
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DISCUSSION 
This is the first study to evaluate MMF pharmacokinetics in children with Lupus nephritis. There 
has been a dramatic improvement in the survival rates of patients with systemic lupus 
erythematosus. The 4 year survival rates in the 1950s was 50% and has currently the 15 year 
survival rate has improved to 80% with the novel treatment options(98). Among them is 
mycophenolate mofetil which has been routinely used in the solid organ transplant patients. 
MMF is as effective and has fewer side effects than steroids and cyclophosphamide(12). 
 
However the ideal dose of MMF in children with lupus nephritis is not described. Traditionally a 
dose 2 to 3 grams per day in divided doses is given. A dose of 900mg/m
2
 has been recommended 
in children as against a dosage of 1200 to 2400 mg/m2 in patients with solid organ transplants. 
These dosing are derived from that recommended for solid organ transplants and there are no 
randomized control trial derived doses available for the treatment of lupus nephritis(90). There 
are a number of literatures suggesting that weight or body surface area dosing of MMF is not 
advisable as it does not predict MPA pharmacokinetics and MPA Pharmacodynamics (99). In 
renal transplantation therapeutic drug monitoring has been developed for individualization of 
doses(90). The inter-individual variability of drug concentration of MMF is a characteristic 
feature of the drug.  There are a number of factors that are described to affect the drug 
concentration like concomitant drug intake namely cyclosporine, tacrolimus and associated co 
morbidities like hypoalbuminemia and severe renal insufficiency(13). 
 
56 
 
 
In solid organ transplanted patients MPA area under the plasma concentration time curve from 0-
12 hrs has been successfully correlated in the outcome (90). Notably the pharmacokinetics in 
SLE is different from the MPA pharmacokinetics of post solid organ transplants who are on 
Cyclosporin A (91,92) . There is a third peak in patients with SLE who have a third peak in the 
AUC due to the absence of calcineurin inhibitors(93,94). Individualized doses aiming at a Target 
concentration of AUC over 12h of 30-60 mg h/l  when measured with high performance liquid 
chromatography or 35 to 70 mg h/l when measured by enzyme multiplied immunotechnique is 
advised for patient undergoing renal transplant (95). Target concentration of MPA that is aimed 
at for the therapy of lupus nephritis in adults is 30-60 mg h/L. The target concentrations of MPA 
in children treated with MMF for SLE is very important as this reflects the clinical outcome and 
the association with side effects. To our knowledge the target concentration of MPA in children 
with Lupus nephritis has not been discussed till date. Hence this study was done to demonstrate 
the inter-individual variability of MPA AUC0-12 levels in children taking MMF for lupus. There 
are no studies to our knowledge done in the pediatric age group in our country. 
 
The setting of the study was at the pediatric rheumatology clinic which runs twice a week. It 
caters to an average of 40 patients per day among which systemic lupus erythematosus accounts 
for about 30% of the cases. The recruitment started in March 2012. Children with lupus nephritis 
who were on MMF for at least 1 month were included. Also the time spacing of the drugs were 
given importance. Children who had not been taking drugs equally spaced through the day were 
asked to come the next month after changing the drug timing. The reason for this is irregular 
therapeutic compliance accounts for variability of the drug levels. 
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25 patients who fulfilled the criteria were recruited over 8 months. 20 patients were girls which 
constituted 80% of the sample size and 5 were boys and contributed to 20% of the sample size. 
This was in concordance with the data about the global sex distribution of the disease although in 
children the female to male preponderance is not as significant as in adults. The female to male 
ratio is about 4.5:1 as against 8 -13:1 in adult onset patients(77). The peak onset of child hood 
SLE occurs during puberty(100). Our patient profile is in accordance with this finding. The mean 
age of our series of patient was 14.8 years. 
The patients’ height, weight and body surface areas were also recorded on the day of 
examination. Mycophenolate mofetil dose for treatment of lupus nephritis is derived from doses 
for solid organ transplants.  Optimum doses for treating lupus nephritis patients are not well 
established. A dose of 2 to 3 grams per day in 2 divided doses is usually given. The pediatric 
transplant dose of 30mg/kg twice daily or 600mg/m
2 
are being traditionally used(59,60). We 
used a dose of 600mg/m
2
 for our patients. 64% of our patients had body surface area between 1-
1.5 m
2
.  32 % of our patients had a body surface area of more than 1.5 m
2
 and 4% of the patients 
had body surface area less than 1 m
2
. 
All our patients who are on MMF have had lupus nephritis diagnosed and staged after a renal 
biopsy. 68% of the patients had class IV nephritis and 32% of them had class III nephritis. The 
indications for use of MMF among our patients were exclusively for lupus nephritis. Many 
studies report the successful use of MMF in the treatment of lupus nephritis(103). MMF is 
indicated in lupus nephritis, dermatitis and other manifestations of SLE(104,105).Among the 
studies the majority  were on treatment of lupus nephritis with MMF after failed cycles of 
cyclophosphamide and has reported dramatic outcome. The corticosteroid sparing effect is of 
particular importance(9). 
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Concomitant medications that the child is on along with that of MMF were recorded. 56% of our 
patients were on prednisolone, 16% were on deflazocort, 84% were on hydroxychloroquine 
(HCQ) and 52% were on calcium and vitamin D supplements.  None of them were on 
cyclosporine or tacrolimus. Plasma concentration of MPA is decreased by concomitant use of 
cyclosporine. Cyclosporine use  inhibits the biliary excretion of MPA 7-0 – glucuronide which is 
the inactive MPA metabolite(106). MMF is often given in combination with other 
immunosuppressants and corticosteroids. Steroids contribute to the MPA metabolism and hence 
decreased the exposure over time(107). 
 
On the day of examination the children are examined and the disease activity is assessed with the 
Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) .   Recently, there are many 
disease activity indices that are validated(108). Among these are the British Isles Lupus 
assessment group (BILAG), the European Consensus Lupus activity measurement (ECLAM), 
the systemic lupus activity measure (SLAM) and the SLE disease activity index(SLEDAI) and 
the safety of estrogen in lupus erythematosus national assessment (SELENA) SLEDAI. Each of 
these indices are designed for longitudinal studies(109,110). In our study we decided to use the 
SLEDAI scoring system for the following reasons. The SLEDAI scoring system unlike BILAG 
is a global index and not organ specific and fewer number of variables (24 Vs 86)(111). Zahr et 
al in their study used both SLEDAI and BILAG index to assess disease activity and successfully 
correlated the  MPA AUC0-12 with disease activity(86). In our study the patients were examined 
using the SLEDAI scoring system and then asked to come to the clinical pharmacology unit the 
next day. 
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In the clinical pharmacology unit, the child will have the mycophenolic acid assay. The child is 
then instructed to take the drug in the lab after the baseline (trough) sample. Later samples are 
taken at 0.5, 1, 1.5, 2, 2.5, 3, 4, 8 and 12 hours after MMF administration. The specimen will be 
centrifuged and plasma separated into a clean eppendorf tube. All specimens will be stored at – 
20
o
C until analysis. We used the high performance liquid chromatography method (HPLC) for 
analysis of MPA AUC 0-12. HPLC is currently the preferred method for acute monitoring of the   
Mycophenolic acid assays(95). There are other methods to determine MPA levels namely the 
EMIT method. In a study done by Weber et al EMIT technique was found to be comparable to 
the HPLC method in determining the MPA levels. However there is cross reactivity with the 
metabolites of mycophenolic acid namely phenolic MPA glucuronide (MPAG) 7-o-MPAG, acyl 
glucuronide (AcMPAG) and phenolic glucoside of MPA(95). 
 
Markers for active nephritis that we included were urine microscopy for blood and protein. For 
quantification of protein we used urine spot protein/Creatinine ratio done by pyrogall indicator 
method. We chose the spot protein Creatinine ratio as against the 24 hour collection mainly for 
the patient’s convenience and the time it saves. Urine for spot protein Creatinine ratio is an 
alternative to the 24 hour urine protein method(112). In a study done in Asia, Absar et al 
concluded that single voided protein/creatinine ratio is an alternative to the 24 hour collection 
method at all levels of GFR(113). Any ratio > 2 was considered nephritic range of proteinuria.  
Proteinuria and hematuria are the most commonly associated findings in lupus nephritis(100). 
Hematuria is almost universal. Nephrotic range of proteinuria is found in 50% of patients with 
lupus at the time of presentation(5). 
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Creatinine was done for all patients prior to the MPA analysis. None of the 25 patients had renal 
insufficiency.  Severe renal insufficiency is known to interfere with the MPA AUC 0-12(97). 
Creatinine was measured in the picric acid method and expressed in mg/dl. Albumin, 
complement levels were included to be independent variables that might influence the MPA 
AUC 0-12.  
 
Complements were done for all the patients by the  In the study done by Zahr et al multivariate 
analysis showed that Creatinine clearance dose of MMF and albumin was significantly 
associated with the MPA AUC0-12.  Complements (C3 and C4) were done by the nephelometry 
method. All co morbidities in the patient on the day of examination were looked for. None of our 
patients had any co morbidities. 
 
 
In our study we have clearly shown a strong association between MPA AUC 0-12 and the disease 
activity as assessed by scoring the disease by the SLEDAI scoring system.  In Zahr et al’s study 
the MPA AUC0-12 correlated with disease activity as assessed by both the SLEDAI and BILAG 
scoring(86). In the study by Rolland a similar finding was observed but however unlike the 
current study disease activity was not assessed by validated indices(114). 
 
We found that the mean MPA AUC0-12 was significantly lower in patients with active disease 
than the patients with inactive disease. It is notable that the two groups (active disease with 
SLEDAI>6 and inactive disease with SLEDAI <6) were similar in mean age, sex distribution, 
similar in concomitant medications intake. 
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We have demonstrated that MPA AUC 0-12 was correlated with SLEDAI, complement level (C3, 
C4) and hemoglobin. Complement level being one of the two main biological markers of SLE 
activity. Zahr et al found that complements, MPA AUC 0-12 along with ds-DNA were associated 
with SLE disease activity.(86)  
 
 
In our multivariate analysis we found that daily MMF doses were recognized as independent 
variables influencing the MPA AUC 0-12. It is very unlikely that other factors like duration of 
treatment with MMF or prior treatment with other drugs could have influenced the results since 
all the patients were on MMF for at least more than 8 weeks. The doses were not modified in the 
past 8 weeks. Moreover the frequencies of concomitant drug intake among the two groups were 
similar. 
 
Therapeutic compliance is a critical issue. This may contribute to variability in the drug levels 
and disease activity(115). This was addressed at the time of recruitment itself. Only patients who 
were on regular medications and dosing were recruited. 
 
Hence it can be said that the dosing of MMF needs to be based on the MPA AUC 0-12 levels. 
Body surface area and weight dosing might not attain adequate drug concentration and thereby 
not leading to good disease control. 
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We have also demonstrated the inter-individual variation of drug concentration per gram of 
MMF which substantiates that fixed daily doses are not recommended. 
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                                       LIMITATIONS 
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Limitations of the study: 
Since it is a cross sectional study the definitive conclusion regarding the association between 
MPA AUC0-12 levels and the SLE activity cannot be established. It can be done through regular 
therapeutic drug monitoring of MPA AUC0-12 levels. 
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                                        CONCLUSIONS 
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Conclusion: 
In conclusion, there is a strong correlation between the disease activity and the MPA AUC0-12 in 
children with lupus nephritis taking MMF. We have also demonstrated an inter-individual 
variability among patients taking a standard dose of MMF. In light of this the inclusion of MMF 
AUC0-12 as parameter in treating children with lupus nephritis patients with MMF is 
recommended. Also prospective pharmacokinetic study needs to be done to evaluate the target 
AUC0-12 for children with lupus nephritis taking MMF. 
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